# China NMPA Drug Inspection - Tianshui Kaiyuan Pharmaceutical Co., Ltd. - Chinese medicinal herbs, such as plantain.

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/tianshui-kaiyuan-pharmaceutical-co-ltd/a461232f-d3f7-4c86-9a7f-be60f8a1a1cc/
Source feed: China

> China NMPA drug inspection for Tianshui Kaiyuan Pharmaceutical Co., Ltd. published April 29, 2022. Drug: Chinese medicinal herbs, such as plantain.. On April 29, 2022, the Gansu Provincial Drug Administration issued a formal announcement regarding the results of the se

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: Tianshui Kaiyuan Pharmaceutical Co., Ltd.
- Publication Date: 2022-04-29
- Drug Name: Chinese medicinal herbs, such as plantain.
- Inspection Finding: Non-compliant with standard requirements
- Action Taken: Relevant authorities are required to take risk control measures and investigate and deal with substandard products in accordance with relevant laws and regulations.
- Summary: On April 29, 2022, the Gansu Provincial Drug Administration issued a formal announcement regarding the results of the second phase of its 2022 drug sampling inspection program. The inspection focused on ensuring pharmaceutical quality standards within the province, specifically identifying failures in traditional herbal preparations.

The document names Tianshui Kaiyuan Pharmaceutical Co., Ltd. as the entity where the sample was collected, while identifying Qingyang Yixiang Pharmaceutical Co., Ltd. as the labeled producer of the non-compliant batch. The specific product in question is the prepared herbal medicine Plantago asiatica. Testing performed by the Tianshui Municipal Drug Inspection and Testing Center revealed that this batch failed to meet the required quality standards.

Operating under the regulatory framework of the National Medical Products Administration (NMPA) and provincial drug safety laws, the Gansu authorities have designated this as a violation of pharmaceutical standards. To mitigate public health risks, the administration has mandated specific required actions for the involved units. These include the immediate implementation of risk control measures and the handling or disposal of the substandard products according to relevant legal protocols. The announcement serves as a public notice to ensure transparency and accountability in the pharmaceutical supply chain.

Company: https://www.globalkeysolutions.net/companies/tianshui-kaiyuan-pharmaceutical-co-ltd/327fc39c-3051-477a-9dbf-127733cdc1a2/